




Patent Docket P0871P4D2

#7
mb
11/13/96

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Dan L. Eaton et al. Serial No.: 08/423,194 Filed: 18 April 1995 For: MPL LIGAND	Group Art Unit: 1812 Examiner: L. Spector <div style="text-align: right;">RECEIVED MAY 24 1996 GPO</div> <div style="text-align: center;"><small>CERTIFICATE OF MAILING</small> <small>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</small> May 10, 1996  Joyce Cohen</div>
--	---

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

The Honorable


Assistant Commissioner of Patents

Sir:

This letter is responsive to an Examiner's Action mailed March 22, 1996 requiring applicants to elect one of two inventions set forth by the Examiner on page 2 of Paper No. 4. Applicants respectfully traverse this restriction requirement. However, to facilitate prosecution on the merits, applicants elect to prosecute claims 1, 2, 6 and 17, drawn to mpl ligands and chimeras thereof, classified in Class 530, subclass 251 and Class 435, subclass 69.1, grouped by the Examiner as invention I. Please cancel without prejudice all nonelected claims.

Respectfully submitted,

GENENTECH, INC.

By: 
Daryl B. Winter
Reg. No. 32,637

Date: May 10, 1996

460 Pt. San Bruno Blvd.
So. San Francisco, CA 94080-4990
Phone: (415) 225-1249
Fax: (415) 952-9881